BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
One lightly wounded after Iranian missile barrage targets northern Israel - 2Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- 3Which Kind of Pet Makes the Incomparable Buddy?
- 4Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
- 5Collection of 7,000-year-old ostrich eggs discovered under sand dunes in southern Israel
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- Vote In favor of Your Favored Menial helper Administration
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- Vote in favor of your Number one kind of juice
- Quandoo to shut restaurant booking platform by end of 2026
- First SpaceX booster for upgraded Starship fails during test in Texas
- UB professor shares his experience on almost becoming an astronaut
- Vote In favor of Your Favored Language Interpretation Administration
- France will build a new aircraft carrier as it increases defense spending
